DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, has signed an exclusive agreement with R-Biomeds, a global pharmaceutical company based in Singapore.
As part of the partnership, DKSH will expand R-Biomeds‘s range of pharmaceuticals, including Oncology, Biosimilars, and Thyroid medicines, to the Cambodian market.
As a strategic partner, DKSH has been collaborating with R-Biomeds to drive growth in Myanmar and, with great success, is now expanding the partnership in Cambodia. DKSH Cambodia will help R-Biomeds grow its business, solidify its brand presence, and gain market share by managing R-Biomeds's distribution and logistics, marketing, and sales. Its experienced teams and broad distribution network will ensure that its products reach modern and traditional trade, hospitals, clinics, other medical channels, and patients in need nationwide.
Rajeev Rawal, Managing Director of R-Biomeds, commented: “We are delighted to partner with DKSH to bring our high-quality medicines to patients in Cambodia. We are confident in DKSH's strong nationwide footprint, extensive distribution network, and expertise to further strengthen R-Biomeds's brands and growth in this market.”
Philip Wray, Vice President of Healthcare at DKSH in Cambodia, said: “With our expertise in Market Expansion Services, we are proud to be R-Biomeds’s trusted and strategic partner. Our partnership demonstrates our commitment to providing patients with better health and quality of life, in line with DKSH's purpose to enrich people's lives and our mission of healthcare for all.”
Subscribe To Our Newsletter & Stay Updated